Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Financial Officer

Pres, Functional Regeneration

Chief Executive Officer

See Remarks

Chief Medical Officer

Senior Exec Vice President

General Counsel

Chief Business Officer

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatm...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-13	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer
2024-04-13	Premium	sold (taxes)	Premium	Premium	Premium	Pres, Functional Regeneration
2024-04-13	Premium	sold (taxes)	Premium	Premium	Premium	Chief Executive Officer
2024-04-13	Premium	sold (taxes)	Premium	Premium	Premium	See Remarks
2024-04-13	Premium	sold (taxes)	Premium	Premium	Premium	See Remarks
2024-03-15	Premium	sold (taxes)	Premium	Premium	Premium	See Remarks
2024-02-17	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer
2024-02-17	Premium	sold (taxes)	Premium	Premium	Premium	See Remarks
2024-02-17	Premium	sold (taxes)	Premium	Premium	Premium	Chief Medical Officer
2024-02-17	Premium	sold (taxes)	Premium	Premium	Premium	Pres, Functional Regeneration
2024-02-17	Premium	sold (taxes)	Premium	Premium	Premium	See Remarks
2024-01-12	Premium	bought	Premium	Premium	Premium	-
2023-10-05	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2023-10-05	Premium	sold	Premium	Premium	Premium	-
2023-09-29	Premium	sold	Premium	Premium	Premium	-
2023-09-29	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2023-07-14	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2023-06-14	Premium	acquired	Premium	Premium	Premium	-
2023-06-14	Premium	acquired	Premium	Premium	Premium	-
2023-06-14	Premium	acquired	Premium	Premium	Premium	-
2023-06-14	Premium	acquired	Premium	Premium	Premium	-
2023-06-14	Premium	acquired	Premium	Premium	Premium	-
2023-06-14	Premium	acquired	Premium	Premium	Premium	-
2023-06-14	Premium	acquired	Premium	Premium	Premium	-
2023-06-14	Premium	acquired	Premium	Premium	Premium	-

CELU - Celularity Inc. Stock Price, Fair Value and News

Latest Insider Trading transactions for CELU